^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    THEO-310

    i
    Other names: THEO-310
    Associations

    News

    Trials
    Company:
    The University of Sheffield, Theolytics
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    over1year
    DEVELOPMENT OF A NOVEL ONCOLYTIC VIRUS -THEO-310 - SPECIALISED FOR TARGETING THE BONE MARROW TUMOUR MICROENVIRONMENT OF MULTIPLE MYELOMA PATIENTS (EHA 2023)
    Oncolytic virus therapies can offer this mechanistically distinct approach for myeloma patients, addressing the heterogeneity of the cancer and its microenvironment... Taken together, THEO-310 represents a new therapeutic option, with a highly differentiated mechanism independent of BCMA, for myeloma patients with relapsed refractory disease. Myeloma, Immunotherapy, Multiple myeloma
    Clinical • Oncolytic virus • IO biomarker
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6)
    |
    THEO-310